



Chuangxingwell

Multi-Drug Rapid Test Kit (Urine)

Package Insert

A rapid, one step screen test for the qualitative detection of drugs and metabolites in human urine. For medical and other professional in vitro diagnostic use only.

Package insert for testing of the following drugs:

Amphetamine 300, Amphetamine 500, Amphetamine, Barbiturates, Benzodiazepines 200, Benzodiazepines, Buprenorphine, Cocaine 150, Cocaine, Fentanyl, Ketamine, Marijuana 20, Marijuana, Marijuana 150, Methadone, EDDP 100 (Methadone metabolite), EDDP 300 (Methadone metabolite), Methamphetamine 300, Methamphetamine 500, Methamphetamine, Methylenedioxymethamphetamine, Morphine 300, Opiate 2000, Oxycodone, Phencyclidine, Propoxyphene, Tramadol and Tricyclic Antidepressants.

INTENDED USE & SUMMARY

Urine based tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The speed and sensitivity of immunoassays have made them the most widely accepted method to screen urine for drugs of abuse.

The Multi-Drug Rapid Test Kit (Urine) is a lateral flow chromatographic immunoassay for the qualitative detection of drugs and drug metabolites in urine at the following cut-off concentrations in urine.¹

Test	Calibrator	Cut-off (ng/mL)
Amphetamine (AMP 300)	d-Amphetamine	300
Amphetamine (AMP 500)	d-Amphetamine	500
Amphetamine (AMP)	d-Amphetamine	1,000
Barbiturates (BAR)	Secobarbital	300
Benzodiazepines (BZO 200)	Oxazepam	200
Benzodiazepines (BZO)	Oxazepam	300
Buprenorphine (BUP)	Buprenorphine	10
Cocaine (COC 150)	Benzoylcegonine	150
Cocaine (COC)	Benzoylcegonine	300
Fentanyl (FTY)	Norfentanyl	20
Ketamine (KET)	Ketamine	1,000
Marijuana (THC 20)	11-nor- Δ^9 -THC-9 COOH	20
Marijuana (THC)	11-nor- Δ^9 -THC-9 COOH	50
Marijuana (THC 150)	11-nor- Δ^9 -THC-9 COOH	150
Methadone (MTD)	Methadone	300
Methadone metabolite (EDDP 100)	2-Ethylidene-1,5-dimethyl-3,3-dipheylpyrrolidine (EDDP)	100
Methadone metabolite (EDDP 300)	2-Ethylidene-1,5-dimethyl-3,3-dipheylpyrrolidine (EDDP)	300
Methamphetamine (MET 300)	d-Methamphetamine	300
Methamphetamine (MET 500)	d-Methamphetamine	500
Methamphetamine (MET)	d-Methamphetamine	1,000
Methylenedioxymethamphetamine (MDMA)	d,l-Methylenedioxymethamphetamine	500
Morphine (MOP 300)	Morphine	300
Opiate (OPI 2000)	Morphine	2,000
Oxycodone (OXY)	Oxycodone	100
Phencyclidine (PCP)	Phencyclidine	25
Propoxyphene (PPX)	Propoxyphene	300
Tramadol (TRA)	Tramadol	100
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000

This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert. **This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.**

PRINCIPLE

The Multi-Drug Rapid Test Kit (Urine) is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against their respective drug conjugate for binding sites on their specific antibody. During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test



REAGENTS

Each test contains specific drug antibody-coupled particles and corresponding drug-protein conjugates. A goat antibody is employed in the control line.

PRECAUTIONS

- For medical and other professional *in vitro* diagnostic use only. Do not use after the expiration date.
- The test strip should remain in the sealed pouch or closed canister until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test strip should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged at room temperature or refrigerated (2-30°C). Avoid hot and sunshine, in a dry place, for a period of 24 months. The test is stable through the expiration date printed on the sealed pouch or label of the closed canister.

The test must remain in the sealed pouch or closed canister until use and it must be used within an hour if the single sealed test strip is opened.

DO NOT FREEZE. Do not use beyond the expiration date.

NOTE: Once the canister has been opened, the remaining test(s) are stable for 90 days only.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear supernatant for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing.

MATERIALS

Materials Provided

- Test strips
- Package insert

Materials Required But Not Provided

- Specimen collection container
- Timer

DIRECTIONS FOR USE


Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testing.

1. Bring the pouch or canister to room temperature before opening it. Remove the test strip from the sealed pouch or canister and use it as soon as possible.

NOTE: For canister packaging, immediately close the canister tightly after removing the required number of the test strip(s). Record the initial opening date on the canister. Once the canister has been opened, the remaining test strip(s) are stable for 90 days only.

2. With arrows pointing toward the urine specimen, **immerse the test strip vertically in the urine specimen for at least 10-15 seconds.** Do not pass the maximum line (MAX) on the test strip when immersing the strip. See the illustration below.

3. Place the test strip on a non-absorbent flat surface, start the timer and wait for the colored line(s) to appear. **Read results at 5 minutes.** Do not interpret the result after 10 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

NEGATIVE:* Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the drug concentration is below the detectable level.

***NOTE:** The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line.

POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region (T). This positive result indicates that the drug concentration exceeds the detectable level.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test. If the problem persists, discontinue using the lot immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the control line region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

- The Multi-Drug Rapid Test Kit (Urine) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.^{2,3}
- There is a possibility that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
- Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- A positive result does not indicate level or intoxication, administration route or concentration in urine.
- A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- The test does not distinguish between drugs of abuse and certain medications.
- A positive result may be obtained from certain foods or food supplements.

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted using the Multi-Drug Rapid Test Kit (Urine) and a commercially available drug rapid test. Testing was performed on approximately 300 specimens previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS. Negative urine specimens were screened initially by Predicate test, 10% negative specimens were confirmed by GC/MS. The following results were tabulated:

Specimen	% Agreement with Commercial Kit													
	AMP 300	AMP 500	AMP	BAR	BZO 200	BZO	BUP**	COC 150	COC	FTY	KET	THC 20	THC	THC 150
Positive	>99%	*	97%	>99%	*	90%	88%	>99%	95%	*	*	*	98%	*
Negative	>99%	*	>99%	99%	*	97%	>99%	>99%	>99%	*	*	*	>99%	*
Total	>99%	*	98%	99%	*	94%	97%	>99%	98%	*	*	*	99%	*

Specimen	MTD	EDDP 100	EDDP 300	MET 300	MET 500	MET	MDMA	MOP 300	OPI 2000	OXY	PCP	PPX	TRA	TCA
	Positive	>99%	*	*	*	>99%	98%	>99%	>99%	99%	96%	98%	>99%	*
Negative	>99%	*	*	*	80%	>99%	99%	>99%	>99%	99%	>99%	>99%	*	>99%
Total	>99%	*	*	*	87%	99%	99%	>99%	>99%	98%	>99%	>99%	*	99%

* **NOTE:** Commercial kit unavailable for comparison testing.

** **NOTE:** BUP was compared to the self-reported use of Buprenorphine.

% Agreement with GC/MS

Specimen	AMP 300	AMP 500	AMP	BAR	BZO 200	BZO	BUP*	COC 150	COC	FTY*	KET	THC 20	THC	THC 150
	Positive	>99%	95%	97%	92%	98%	97%	98%	99%	96%	99%	>99%	87%	96%
Negative	99%	>99%	95%	98%	99%	95%	>99%	99%	90%	90%	95%	99%	97%	96%
Total	99%	98%	96%	95%	99%	96%	>99%	99%	93%	93%	95%	95%	96%	96%

Specimen	MTD	EDDP 100	EDDP 300	MET 300	MET 500	MET	MDMA	MOP 300	OPI 2000	OXY	PCP	PPX	TRA*	TCA**
	Positive	99%	98%	>99%	97%	>99%	99%	>99%	>99%	98%	99%	>99%	94%	99%
Negative	94%	>99%	94%	>99%	97%	94%	98%	94%	97%	98%	96%	99%	96%	89%
Total	96%	99%	96%	98%	98%	96%	99%	97%	98%	99%	97%	96%	97%	91%

* **NOTE:** BUP, FTY and TRA were based on LC/MS data instead of GC/MS.

** **NOTE:** TCA was based on HPLC data instead of GC/MS.

Analytical Sensitivity

A drug-free urine pool was spiked with drugs to the concentrations at \pm 50% cut-off and \pm 25% cut-off. The results are summarized below.

Drug Conc. (Cut-off range)	AMP 300		AMP 500		AMP		BAR		BZO 200		BZO		BUP		COC 150		COC	
	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	60	0	30	0	90	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	60	0	30	0	90	0	30	0	30	0
-25% Cut-off	27	3	25	5	22	8	27	3	60	0	27	3	75	15	24	6	30	0
Cut-off	13	17	11	19	12	18	22	8	22	38	11	19	60	30	14	16	4	26
+25% Cut-off	4	26	5	25	2	28	8	22	2	58	5	25	31	59	7	23	0	30
+50% Cut-off	0	30	0	30	0	30	2	28	0	60	0	30	0	90	0	30	0	30

Drug Conc. (Cut-off range)	FTY		KET		THC 20		THC		THC 150		MTD		EDDP 100		EDDP 300		MET 300	
	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	90	0	90	0	30	0	30	0	30	0	90	0	90	0	90	0	30	0
-50% Cut-off	90	0	90	0	30	0	30	0	90	0	29	1	90	0	90	0	30	0
-25% Cut-off	82	8	61	29	27	3	12	18	90	0	24	6	90	0	90	0	27	3
Cut-off	48	42	20	70	24	6	1	29	46	44	21	9	37	53	51	39	15	15
+25% Cut-off	11	79	2	88	17	13	1	29	5	85	2	28	8	82	14	76	4	26
+50% Cut-off	0	90	0	90	5	25	0	30	0	90	0	30	0	90	0	90	0	30

Drug Conc. (Cut-off range)	MET 500		MET		MDMA		MOP		OPI 2000		OXY		PCP		PPX		TRA		TCA	
	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	90	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	90	0	30	0
-25% Cut-off	23	7	30	0	26	4	25	5	25	5	30	0	19	11	24	6	90	0	29	1
Cut-off	13	17	18	12	17	13	17	13	15	15	18	12	16	14	17	13	61	29	18	12
+25% Cut-off	8	22	1	29	4	26	1	29	6	24	6	24	6	24	7	23	21	69	5	25
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	2	88	0	30

Analytical Specificity

The following table lists the concentration of compounds (ng/mL) that are detected positive in urine by the Multi-Drug Rapid Test Kit (Urine) at 5 minutes.

AMPHETAMINE 300		MARIJUANA 20	
d-Amphetamine	300	11-nor- Δ^9 -THC-9 COOH	20
d,l-Amphetamine	390	Cannabinol	12,500
l-Amphetamine	50,000	11-nor- Δ^8 -THC-9 COOH	20
p-Hydroxyamphetamine	1,560	Δ^8 -THC	10,000
p-Hydroxynorephedrine	100,000	Δ^9 -THC	12,500
3,4-Methylenedioxyamphetamine (MDA)	1,560	MARIJUANA	
β -Phenylethylamine	100,000	11-nor- Δ^9 -THC-9 COOH	50
Phenylpropanolamine (d,l-Norephedrine)	100,000	Cannabinol	20,000
Tyramine	100,000	11-nor- Δ^8 -THC-9 COOH	30
AMPHETAMINE 500		Δ^8 -THC	15,000
d-Amphetamine	500	Δ^9 -THC	15,000
l-Amphetamine	1,500	MARIJUANA 150	
3,4-Methylenedioxyamphetamine (MDA)	800	11-nor- Δ^9 -THC-9 COOH	150
Phentermine	1,500	Cannabinol	25,000
β -Phenylethylamine	50,000	11-nor- Δ^8 -THC-9 COOH	500
Tryptamine	50,000	Δ^8 -THC	25,000
Tyramine	25,000	Δ^9 -THC	25,000
AMPHETAMINE		METHAMPHETAMINE 300	
d-Amphetamine	1,000	d-Methamphetamine	300
d,l-Amphetamine	3,000	d,l-Amphetamine	100,000
l-Amphetamine	50,000	Chloroquine	25,000
d,l-3,4-Methylenedioxyamphetamine (MDA)	2,000	Ephedrine	100,000
Phentermine	3,000	(1R,2S)-l-Ephedrine	100,000
BARBITURATES		l-Epinephrine	50,000
Secobarbital	300	Fenfluramine	12,500
Alphenal	150	p-Hydroxymethamphetamine	25,000
Amobarbital	300	Mephentermine	50,000
Aprobarbital	200	l-Methamphetamine	3,125
Butobarbital	75	3,4-Methylenedioxyamphetamine (MDMA)	780
Butalbital	2,500	Trimethobenzamide	25,000
Butethal	100	METHAMPHETAMINE 500	
Cyclopentobarbital	600	d-Methamphetamine	500
Pentobarbital	300	d,l-Amphetamine	75,000
Phenobarbital	100	d-Amphetamine	50,000
BENZODIAZEPINES 200		Chloroquine	12,500
Oxazepam	200	(1R,2S)-l-Ephedrine	50,000
Alprazolam	30	p-Hydroxymethamphetamine	15,000
7-Aminoclonazepam	4,000	Mephentermine	25,000
7-Aminoflunitrazepam	390	l-Methamphetamine	4,000
7-Aminonitrazepam	625	3,4-Methylenedioxyamphetamine (MDMA)	1,000
Bromazepam	390	l-Phenylephrine	100,000
Chlordiazepoxide	300	β -Phenylethylamine	75,000
Clobazam	48	METHAMPHETAMINE	
Clorazepate	97	d-Methamphetamine	1,000
Desalkylflurazepam	1,560	p-Hydroxymethamphetamine	30,000
Diazepam	97	Mephentermine	50,000
Estazolam	125	l-Methamphetamine	8,000

Flunitrazepam	25,000	d,l-3,4-Methylenedioxyamphetamine (MDMA)	2,000
α -Hydroxylprazolam	30	METHYLENEDIOXYMETHAMPHETAMINE (MDMA)	
d-Lorazepam	3,125	d,l-3,4-Methylenedioxyamphetamine (MDMA)	500
Midazolam	195	d,l-3,4-Methylenedioxyamphetamine (MDA)	3,000
Nitrazepam	780	3,4-Methylenedioxyethylamphetamine (MDEA)	300
Norchlordiazepoxide	780	MORPHINE 300	
Nordiazepam	780	Morphine	300
Temazepam	33	Codeine	300
Triazolam	150	Ethylmorphine	6,250
BENZODIAZEPINES		Hydrocodone	50,000
Oxazepam	300	Hydromorphone	3,125
Alprazolam	196	Levorphanol	1,500
Bromazepam	1,562	6-Monoacetylmorphine (6-MAM)	400
Chlordiazepoxide	1,562	Morphine 3- β -D-glucuronide	1,000
Clobazam	98	Norcodeine	6,250
Clonazepam	781	Normorphine	100,000
Clorazepate	195	Oxycodone	30,000
Delorazepam	1,562	Oxymorphone	100,000
Desalkylflurazepam	390	Procaine	15,000
Diazepam	195	Thebaine	6,250
Estazolam	2,500	OPIATE 2000	
Flunitrazepam	390	Morphine	2,000
α -Hydroxylprazolam	1,262	Codeine	2,000
d,l-Lorazepam	1,562	Ethylmorphine	5,000
RS-Lorazepam glucuronide	156	Hydrocodone	12,500
Midazolam	12,500	Hydromorphone	5,000
Nitrazepam	98	Levorphanol	75,000
Norchlordiazepoxide	195	6-Monoacetylmorphine (6-MAM)	5,000
Nordiazepam	390	Morphine 3- β -D-glucuronide	2,000
Temazepam	98	Norcodeine	12,500
Triazolam	2,500	Normorphine	50,000
BUPRENORPHINE		Oxycodone	25,000
Buprenorphine	10	Oxymorphone	25,000
Buprenorphine 3-D-glucuronide	15	Procaine	150,000
Norbuprenorphine	20	Thebaine	100,000
Norbuprenorphine 3-D-glucuronide	200	OXYCODONE	
COCAINE 150		Oxycodone	100
Benzoyllecgonine	150	Hydrocodone	6,250
Cocaine	400	Hydromorphone	50,000
Cocaethylene	6,250	Levorphanol	50,000
Ecgonine	12,500	Naloxone	37,500
Ecgonine methylester	50,000	Naltrexone	37,500
COCAINE		Oxymorphone	200
Benzoyllecgonine	300	PHENCYCLIDINE	
Cocaine	780	Phencyclidine	25
Cocaethylene	12,500	4-Hydroxyphencyclidine	12,500
Ecgonine	32,000	PROPOXYPHENE	
EDDP 100		d-Propoxyphene	300
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)	100	d-Norpropoxyphene	300
EDDP 300		TRAMADOL	
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)	300	Cis-tramadol	100
FENTANYL		n-Desmethyl-cis-tramadol	195
Norfentanyl	20	o-Desmethyl-cis-tramadol	6,250
Alfentanyl	562,500	Phencyclidine	100,000
Bupirone	12,500	Procyclidine	100,000
Fenfluramine	37,500	d,l-O-Desmethyl venlafaxine	25,000
Fentanyl	100	TRICYCLIC ANTIDEPRESSANTS	
Sufentanyl	57,500	Nortriptyline	1,000
KETAMINE		Amitriptyline	1,500
Ketamine	1,000	Clomipramine	12,500
Pentobarbital	50,000	Desipramine	200
Secobarbital	100,000	Doxepin	2,000
Norketamine	50,000	Imipramine	400
METHADONE		Maprotiline	2,000
Methadone	300	Nordoxepin	1,000
Doxylamine	50,000	Promazine	1,500
		Promethazine	25,000
		Trimipramine	3,000

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or Amphetamine 300, Amphetamine 500, Amphetamine, Barbiturates, Benzodiazepines 200, Benzodiazepines, Buprenorphine, Cocaine 150, Cocaine, Fentanyl, Ketamine, Marijuana 20, Marijuana, Marijuana 150, Methadone, EDDP 100 (Methadone metabolite), EDDP 300 (Methadone metabolite), Methamphetamine 300, Methamphetamine 500, Methamphetamine, Methylenedioxyamphetamine, Morphine 300, Opiate 2000, Oxycodone, Phencyclidine, Propoxyphene, Tramadol and Tricyclic Antidepressants positive urine. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test Kit (Urine) at a concentration of 100 μ g/mL.

Non Cross-Reacting Compounds

4-Acetamidophenol	Dextromethorphan	Ketoprofen	Phenothiazine
Acetone	Diclofenac	Labetalol	Prednisolone
Acetophenetidin	Dicyclomine	Lidocaine	Prudisone
Acetylsalicylic acid	Diffunisal	Lindane	d,l-Propranolol
Albumin	Digoxin	Lithium	Quinacrine
alpha-Naphthaleneacetic Acid	4-Dimethylaminoantipyrine	Loperamide	Quinidine
Aminopyrine	Diphenhydramine	l-Thyroxine	Quinine
Amoxapine	5,5-Diphenylhydantoin	Meperidine	R(-) Deprenyl
Amoxicillin	EMDP	Meprobamate	Riboflavin
Ampicillin	Erythromycin	Methaqualone	Salicylic acid
Apomorphine	β -Estradiol	Methoxyphenamine	Serotonin
Ascorbic acid	Estrone-3-sulfate	Methylphenidate	Seroquel
Aspartame	Ethyl alcohol	Metoprolol	Sertraline
Atropine	Ethyl-p-aminobenzoate	N-Acetylprocainamide	Sodium Chloride
Benzilic acid	Etodolac	Nalidixic acid	Sulfamethazine
Benzoic acid	Famprofazone	Nalorphine	Sulindac
Benzydamine	Fluoxetine	Naproxen	Tetracycline
Brompheniramine	Fluoxetine	Niacinamide	Tetrahydrocortison-3-acetate
Caffeine	Furosemide	Nifedipine	Tetrahydrozoline
Cannabidiol	Genticic acid	Nimesulide	Theophylline
Chloral Hydrate	d-Glucose	Norethindrone	Thiamine
Chloramphenicol	Guaiaicol Glyceryl Ether	Noscapine	Thiordazine
Chloroquine	Hemoglobin	d,l-Octopamine	Tolbutamide
Chlorothiazide	Hydralazine	Orphenadrine	Trans-2-phenylcyclopropylamine
Chlorpromazine	Hydrochlorothiazide	Oxalic acid	Trazodone
Chlorprothixene	Hydrocortisone	Oxolinic acid	Triamterene
Cholesterol	o-Hydroxyhippuric acid	Oxymetazoline	Trifluoperazine
Cimetidine	3-Hydroxytyramine	Papaverine	Trimethoprim
Clonidine	Ibuprofen	Pemoline	d,l-Tryptophan
Cortisone	Iproniazid	Penicillin	d,l-Tyrosine
l-Cotinine	Isoproterenol	Pentazocine	Uric acid
Creatinine	Isosuprine	Phenelzine	Verapamil
Deoxycorticosterone	Kanamycin	Pheniramine	Zomepirac

BIBLIOGRAPHY

- Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735
- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986



Manufacturer
Jinan Chuangxingwell Biotech Co., Ltd.
Add.: Building 1-2B-402, Liando U Valley, Gangyuan Sixth Road, Jinan Zhangjin Comprehensive Bonded Zone, Gaoxin District, Jinan city, Shandong Province, China
Tel.: +86-0531-88894020
Email: s@1stiot.com



Riomavix S.L.
Add.: Calle de Almansa 55, 1D, Madrid 28039 Spain
E-mail: leis@riomavix.com
Tel.: +34 658 396 230
(SRN: ES-AR-000001202)

INDEX OF SYMBOLS

	Caution		In Vitro Diagnostic Medical Device
	Manufacturer		Date of Manufacture
	CE Marking		Do Not Re-use
	Keep Dry		Keep Away From Sunlight
	Batch Code		Do Not Use if Package is Damaged
	Catalogue Number		Contains Sufficient for <n> Tests
	Use-By Date		Temperature Limit
	Authorized representative in the European Community		